ICU Medical, Inc. reported its financial results for the first quarter ended March 31, 2025, with total revenues of $604.7 million, an increase from $566.7 million in the prior year period. The company achieved a GAAP gross profit of $210.1 million, leading to a GAAP gross margin of 35%, up from 33% in Q1 2024.
The company reported a GAAP net loss of $(15.5) million, or $(0.63) per diluted share, a notable improvement from a net loss of $(39.5) million, or $(1.63) per diluted share, in Q1 2024. Adjusted diluted earnings per share for the quarter were $1.72, significantly higher than $0.96 in the prior year, and Adjusted EBITDA increased to $99.4 million from $78.8 million in Q1 2024.
Segment performance showed Consumables revenue growing to $266.2 million, Infusion Systems revenue reaching $166.3 million, and Vital Care revenue at $172.2 million, all showing year-over-year increases. CEO Vivek Jain stated that the first quarter results were generally in line with the company's expectations, reflecting progress in operational efficiencies and pricing strategies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.